This neuroscience article previews a PET imaging study that examines muscarinic M1 receptor availability in living schizophrenia patients, offering context for implications in research and treatment decisions.
Key Takeaways
- Researchers delivered the world’s first in vivo (in a living organism)
- Findings provide immediate biological reinforcement for newly approved therapies like xanomeline–trospium (COBENFY™)
- Reductions in M1 receptors affect several brain regions involved in cognition, learning, memory, and executive function